VIR
NASDAQ · Biotechnology
Vir Biotechnology Inc
$8.57
-0.27 (-3.05%)
Financial Highlights (FY 2026)
Revenue
71.78M
Net Income
-504,907,326
Gross Margin
98.9%
Profit Margin
-703.4%
Rev Growth
-59.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.9% | 98.9% | 41.4% | 41.4% |
| Operating Margin | -791.3% | -712.1% | -31.7% | -35.1% |
| Profit Margin | -703.4% | -668.2% | -27.2% | -30.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 71.78M | 176.09M | 113.39M | 105.81M |
| Gross Profit | 70.96M | 174.09M | 46.97M | 43.83M |
| Operating Income | -567,939,209 | -1,254,036,526 | -35,981,507 | -37,098,247 |
| Net Income | -504,907,326 | -1,114,859,159 | -30,823,495 | -32,439,743 |
| Gross Margin | 98.9% | 98.9% | 41.4% | 41.4% |
| Operating Margin | -791.3% | -712.1% | -31.7% | -35.1% |
| Profit Margin | -703.4% | -668.2% | -27.2% | -30.7% |
| Rev Growth | -59.2% | -59.2% | +24.3% | +5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 432.19M | 355.41M |
| Total Equity | — | — | 459.65M | 428.15M |
| D/E Ratio | — | — | 0.94 | 0.83 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -569,842,810 | -1,328,141,976 | -42,153,177 | -39,538,454 |
| Free Cash Flow | — | — | -22,930,380 | -17,215,226 |